Tap Pharmaceuticals, 370 Interlocken Blvd, Broomfield, CO 80021, US

N30 Pharmaceuticals, headquartered in Boulder, Colorado, is a biopharmaceutical company founded in 2007. They are focused on developing innovative disease modifying therapies, with a particular emphasis on cystic fibrosis. N30 Pharma's lead program involves the development of small molecule inhibitors of GSNOR, an enzyme that plays a crucial role in the regulation of nitric oxide signaling. Their proprietary inhibitors have shown promising results in preclinical models of inflammatory lung disease, preserving the levels of GSNO and potentially offering therapeutic benefits. N30 Pharmaceuticals is dedicated to advancing their novel class of therapies that target GSNO and its role in organ repair and healing. With a broad portfolio of potent inhibitors, they aim to address the decreased GSNO levels associated with inflammatory lung disease. By developing safe and effective treatments, N30 Pharma is committed to making a positive impact on patients with cystic fibrosis and other related conditions. Their research and development efforts align with the rigorous regulatory processes of the FDA and other international agencies to ensure the quality and efficacy of their pharmaceutical products.Generated from the website

Experian

Legacy Partners

Knowledge Tech Solutions Inc

Hejny, Leann